Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

9.15USD
18 May 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.15
Open
$9.20
Day's High
$9.25
Day's Low
$9.10
Volume
66,933
Avg. Vol
104,687
52-wk High
$15.95
52-wk Low
$6.80

Select another date:

Thu, Apr 26 2018

BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56

* CYTOKINETICS, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75

* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Cytokinetics Announces Progress Against Vision 2020

* CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​

Cytokinetics sinks on abandoning ALS drug after failed trial

Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

UPDATE 4-Cytokinetics sinks on abandoning ALS drug after failed trial

Nov 21 Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS

* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​

Cytokinetics' neuro-degenerative drug fails late-stage trial

Nov 21 Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.

Select another date: